Clinical Trials List
2018-01-29 - 2023-06-20
Others
Terminated2
ICD-10D46.9
Myelodysplastic syndrome, unspecified
ICD-10D64.9
Anemia, unspecified
ICD-9238.7
Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues
ICD-9285.9
Anemia, unspecified
A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
FibroGen, Inc.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Li-Yuan Bai Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 蔡郁棻 Division of Hematology & Oncology
- Yi-Chang Liu Division of Hematology & Oncology
- Hui-Hua Hsiao Division of Hematology & Oncology
- Hui-Ching Wang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
0 participants
-
Global
184 participants
